Loading
Crohn's Disease / Mirikizumab / Tirzepatide · Phase 3 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 3 trial registration without results. The study is designed to evaluate whether mirikizumab combined with tirzepatide improves simultaneous clinical remission, endoscopic remission, and weight reduction in adults with moderately to severely active Crohn's disease and obesity or overweight, with a maximum duration of 61 weeks.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Crohn's Disease, Obesity or Overweight; age from 18 Years; to 70 Years. Intervention: Mirikizumab + Tirzepatide; Mirikizumab + Placebo. Compared with: Mirikizumab and placebo. n = 290. 183 sites across 22 countries.
This is an active Phase 3 trial registration without results. The study is designed to evaluate whether mirikizumab combined with tirzepatide improves simultaneous clinical remission, endoscopic remission, and weight reduction in adults with moderately to severely active Crohn's disease and obesity or overweight, with a maximum duration of 61 weeks.
This is a registry record only; no efficacy or safety results are reported.
The source did not state who this applies to in practice.
This is a Phase 3 registry record with no reported results; the study is actively recruiting and designed to test a combination approach in a dual-disease population, but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06937099). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 290 participants (ESTIMATED). Conditions: Crohn's Disease, Obesity or Overweight. Interventions: DRUG: Mirikizumab; DRUG: Mirikizumab; DRUG: Tirzepatide; DRUG: Placebo. Primary outcome measures: Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction , Week 52. Brief summary: The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.